THE DEAL, AT A GLANCE
From the announcementAravive
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAravive raised $50M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersAravive is positioned around batiraxcept as an AXL/GAS6 inhibitor for cancer and fibrosis, with new Growth Round capital directed toward advancing batiraxcept to Phase 3…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Aravive · Financing Record
Explore source-linked visual explanations for Aravive. Unsupported claims are withheld while source review continues.
Record 1667 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →